The monoclonal antibody treatment from GlaxoSmithKline (GSK) and Vir BioTechnology protects well against the Omicron subvariant that is becoming more prevalent in the United States, the companies said Feb. 10.Preclinical data suggest that sotrovimab, the monoclonal, “retains neutralizing activity against the BA.2 subvariant of Omicron ,” the companies said in a press release.The data, based on pseudovirus and pharmacokinetic testing, was not made public. A Vir spokesperson didn’t respond when asked why. The companies said the results are being shared with government authorities around the world and that they plan on publishing them on the preprint server bioRxiv in the...